HRP20151006T1 - Terapeutska uporaba diaminofenotiazina - Google Patents

Terapeutska uporaba diaminofenotiazina Download PDF

Info

Publication number
HRP20151006T1
HRP20151006T1 HRP20151006TT HRP20151006T HRP20151006T1 HR P20151006 T1 HRP20151006 T1 HR P20151006T1 HR P20151006T T HRP20151006T T HR P20151006TT HR P20151006 T HRP20151006 T HR P20151006T HR P20151006 T1 HRP20151006 T1 HR P20151006T1
Authority
HR
Croatia
Prior art keywords
compound
daptz
crystalline
stable
reduced form
Prior art date
Application number
HRP20151006TT
Other languages
English (en)
Croatian (hr)
Inventor
Claude Michel Wischik
Damon Jude Wischik
John Mervyn David Storey
Charles Robert Harrington
Original Assignee
Wista Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd. filed Critical Wista Laboratories Ltd.
Publication of HRP20151006T1 publication Critical patent/HRP20151006T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20151006TT 2007-10-03 2008-10-01 Terapeutska uporaba diaminofenotiazina HRP20151006T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96054407P 2007-10-03 2007-10-03
PCT/GB2008/003315 WO2009044127A1 (en) 2007-10-03 2008-10-01 Therapeutic use of diaminophenothiazines
EP08806465.4A EP2205245B1 (en) 2007-10-03 2008-10-01 Therapeutic use of diaminophenothiazines

Publications (1)

Publication Number Publication Date
HRP20151006T1 true HRP20151006T1 (hr) 2015-10-23

Family

ID=40220337

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151006TT HRP20151006T1 (hr) 2007-10-03 2008-10-01 Terapeutska uporaba diaminofenotiazina

Country Status (16)

Country Link
US (3) US9149481B2 (enExample)
EP (2) EP2205245B1 (enExample)
JP (1) JP5592261B2 (enExample)
CN (1) CN101883567B (enExample)
AU (1) AU2008306688B2 (enExample)
BR (1) BRPI0818182B1 (enExample)
CA (2) CA3027974C (enExample)
DK (2) DK2954932T3 (enExample)
ES (2) ES2546819T3 (enExample)
HR (1) HRP20151006T1 (enExample)
HU (1) HUE025199T2 (enExample)
MY (1) MY161656A (enExample)
PL (2) PL2205245T3 (enExample)
PT (2) PT2954932T (enExample)
SI (2) SI2205245T1 (enExample)
WO (1) WO2009044127A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
ES2655492T3 (es) 2010-11-30 2018-02-20 Wista Laboratories Ltd. Formulaciones que comprenden cloruro de metiltioninio
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
CN103864717B (zh) * 2014-04-04 2015-11-11 山东理工大学 一种针状亚甲基白晶体的制备方法
CN103923036B (zh) * 2014-04-24 2015-09-16 山东理工大学 一种棒状亚甲基蓝晶体的制备方法
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3,7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN111956245A (zh) * 2020-08-27 2020-11-20 复旦大学附属肿瘤医院 术后认知功能障碍预防评估方法,系统和装置
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
WO2024163665A1 (en) * 2023-01-31 2024-08-08 Unlearn.AI, Inc. Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
CN104119294B (zh) * 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
DK2004155T3 (en) * 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
MY162313A (en) * 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) * 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas

Also Published As

Publication number Publication date
US20160030444A1 (en) 2016-02-04
SI2205245T1 (sl) 2015-10-30
JP2010540606A (ja) 2010-12-24
CA2701075A1 (en) 2009-04-09
JP5592261B2 (ja) 2014-09-17
SI2954932T1 (sl) 2019-01-31
US10188658B2 (en) 2019-01-29
ES2546819T3 (es) 2015-09-28
PL2205245T3 (pl) 2015-12-31
CN101883567B (zh) 2012-12-26
CA3027974A1 (en) 2009-04-09
US20100290986A1 (en) 2010-11-18
MY161656A (en) 2017-04-28
BRPI0818182A2 (pt) 2020-06-23
DK2205245T3 (en) 2015-09-28
CA2701075C (en) 2019-02-12
AU2008306688B2 (en) 2014-05-22
WO2009044127A1 (en) 2009-04-09
EP2205245A1 (en) 2010-07-14
PL2954932T3 (pl) 2019-04-30
HK1211889A1 (en) 2016-06-03
US9149481B2 (en) 2015-10-06
AU2008306688A1 (en) 2009-04-09
EP2954932B1 (en) 2018-09-19
US20190151329A1 (en) 2019-05-23
EP2205245B1 (en) 2015-06-24
PT2205245E (pt) 2015-10-13
HK1140675A1 (en) 2010-10-22
BRPI0818182B1 (pt) 2021-10-19
HUE025199T2 (en) 2016-01-28
CA3027974C (en) 2022-03-15
ES2701089T3 (es) 2019-02-20
DK2954932T3 (en) 2018-12-17
EP2954932A1 (en) 2015-12-16
CN101883567A (zh) 2010-11-10
PT2954932T (pt) 2018-12-12

Similar Documents

Publication Publication Date Title
JP2010540606A5 (enExample)
IT1266565B1 (it) Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
SI2004155T1 (en) Inhibitors of protein aggregation
ES2308689T3 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen.
EP3689346B1 (en) 3,6-disubstituted xanthylium salts for treating tauopathies
US10227376B2 (en) Radiolabeled cationic steroid antimicrobials and diagnostic methods
NO2013002I2 (no) Aklidiniumsalt med et farmaøytisk akseptabelt anion av en mono-eller polyvalent syre, spesielt aklidiniumbromid
FI941987L (fi) Uudet aminohappojohdannaiset, menetelmät niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset
PT2057136E (pt) Processos de síntese e/ou purificação de compostos diaminofenotiazínio
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
ES8200857A1 (es) Procedimiento de preparacion de un nuevo eter basico o de una sal de adicion acida o sal cuaternaria del mismo,farma- ceuticamente aceptable
DE59401919D1 (de) Neue 11-Benzaldoxim-17beta methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
BR9510410A (pt) Composto, composição farmacêutica ou veterinária, processo para produzir o composto e uso do composto
ES2711075T3 (es) Compuestos para su uso en el tratamiento de trastornos cognitivos
ATE265998T1 (de) Propancarbonsäure-amidoxim derivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese entahlten
ATE344240T1 (de) Kondensierte heterozyklische verbindungen und ihre pharmazeutische anwendung
HRP20100622T1 (hr) Novi derivati cikloalkiliranog benzotiadizina, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
ATE19627T1 (de) Substituierte pyrimidin-2-one, ihre salze, verfahren zu deren herstellung und diese enthaltende zusammensetzungen.
AU656674B2 (en) New thiochroman compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
MY138865A (en) New tricyclic azepine compounds, a process for their preparation and pharmaceutical compositions containing them
AU2002349043B2 (en) Ultrapure oral fludara formulation with a fast releasing active substance
BR0201286A (pt) Derivados da 4-amino-piridopirimidina substituìda com biciclos
ATE165362T1 (de) Neue derivate des 2-(1h)-chinolinones, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
JPS5942315A (ja) 下痢治療用薬剤
AR016184A1 (es) INDOLES 5-HETEROARIL SUSTITUIDOS, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, LA UTILIZACIoN DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO Y PARA LA PREPARACIoN DE UN COMPUESTO RADIO-MARCADO.